Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Manufacturing
  • PCI adds US sterile fill/finish capabilities through $1B global expansion drive
  • Manufacturing

PCI adds US sterile fill/finish capabilities through $1B global expansion drive

BioSpace

Amid disruption to the outsourced fill/finish market, PCI is investing $100 million to more than double the capacity to fill ready-to-use prefilled syringes and cartridges at its San Diego campus.

Read full story

pharminent May 4, 2026 (Last updated: May 4, 2026)

BioSpace

Amid disruption to the outsourced fill/finish market, PCI is investing $100 million to more than double the capacity to fill ready-to-use prefilled syringes and cartridges at its San Diego campus.

Read full story

Post navigation

Previous: First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial
Next: Gene therapy’s evidence problem–lessons from recent FDA decisions

Related Stories

  • Manufacturing

BMS banks on Texas for $2.3bn multi-modal manufacturing facility

pharminent August 11, 2026
  • Manufacturing

AsymBio to secure $184m to support growth in biologics manufacturing

pharminent August 5, 2026
  • Manufacturing

Lilly and Resilience invest $750M in diabetes and obesity drug device supply

pharminent July 31, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.